First Patient Receives Anti-Ageing Gene Therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- First patient received a world-first gene therapy designed to reprogram ageing cells to a younger state, in a trial targeting age-related vision decline
- Ian Sample explains the science behind the therapy, which uses gene-editing tools to reset cellular age markers in retinal tissue
- John Knoepfler discusses the broader implications of cellular rejuvenation, noting its potential to expand beyond vision if safety is confirmed
- Research team focused the initial trial on retinal cells due to their accessibility and well-mapped role in age-related degeneration
- Therapy developers aim to demonstrate safety first, with future applications in other tissues dependent on early trial outcomes
Why it matters: If proven safe, this therapy could shift the standard for treating age-related diseases from symptom management to biological reversal, opening pathways for regenerative treatments in other tissues. The focus on measurable cellular ageing markers provides a clear benchmark for success, which could accelerate regulatory interest in rejuvenation therapies.
